Cor­cept plots fu­ture for ALS drug that flunked Phase 2, cit­ing sur­vival analy­sis

Cor­cept Ther­a­peu­tics is piec­ing to­geth­er a path for­ward for an ex­per­i­men­tal drug that failed a mid-stage ALS study af­ter new da­ta showed the treat­ment boost­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER